Fat loss foundations — Canada Peptides

Loading

Fat loss foundations — Canada Peptides

The metabolic domain has moved the furthest of any peptide class in the last five years. Incretin mimetics (GLP-1, GIP, glucagon agonists) now have the largest, cleanest human dataset of any peptide family. Paired with compounds that act through different pathways — catecholamine reuptake inhibition, HGH-fragment lipolysis — they form a well-studied compositional stack.

This protocol is designed for methodical fat loss with a preserved lean-mass profile. It is not a crash protocol. Runs 12–16 weeks.

Core compound — Retatrutide

Retatrutide is the triple agonist — GLP-1, GIP, and glucagon — with the strongest weight-loss signal in published Phase 2 data to date. Weekly subcutaneous dosing. Start low (1–2 mg/week) for two weeks to assess GI tolerance before titrating.

Catecholamine adjunct — Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine). It acts through a fundamentally different pathway from incretin mimetics — appetite suppression plus increased basal metabolic activity. Low-dose (0.25–0.5 mg daily) is the published research range.

Lipolytic adjunct — AOD-9604

AOD-9604 is the HGH C-terminal fragment isolated specifically for the lipolytic signaling of growth hormone without the downstream IGF-1 effect. Less dramatic than the GLP-1 class, but clean — minimal side-effect profile, no insulin-sensitivity interaction with the core compound.

Proposed dosing window

Compound	Frequency	Published range
Retatrutide	Weekly	1–12 mg
Tesofensine	Daily	0.25–1.0 mg
AOD-9604	5x weekly	300 mcg

Endpoints to measure

Body weight (weekly, same time/condition)
Waist circumference (weekly, at the navel)
Resting heart rate (daily, from a fixed wearable)
Subjective satiety (10-point scale, logged at meals)
Fasting glucose (weekly)

When to stop

The published Retatrutide trials dose-escalate over 18–36 weeks. Stop titrating when your weekly body-weight loss exceeds 1.5% — faster than that is where lean mass begins to be consumed alongside adipose. Hold at the effective dose rather than pushing higher.